EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Nanobody-Based CAR NK Cells for Possible Immunotherapy of Mesothelin + Tumors

Dana Jung iD, Eunjeong Choi, Young-Hee Jeoung, Juheon Lee, Eun-Yeung Gong, Seo-Gyeong Jo, Kyunghee Noh, Kyungsoo Ha, Gabbine Wee, Hyeran Kim, Juyeon Jung, Seokho Kim iD

Immune Network · 2025 · 25 (3)

DOI: 10.4110/in.2025.25.e23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immune Network, 2025. Verfasst von Dana Jung und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Science, Graduate School of Dong-A University, Busan 49315, Korea. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Research Institute of Bioscience and Biotechnology, National Research Council of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric Ag receptor (CAR)-engineered immune cells have demonstrated remarkable clinical efficacy, particularly in hematologic malignancies. Central to their success is the Ag-binding domain of the CAR, which governs both target specificity and therapeutic efficacy. Nanobodies (Nbs) possess a single-domain architecture and smaller molecular size, making them particularly amenable to the construction of tandem CARs that can co-target multiple Ags. This structural flexibility is advantageous for addressing tumor heterogeneity and reducing the risk of Ag escape in solid malignancies. Here, we developed mesothelin (MSLN)-specific nanobody-based chimeric Ag receptor-NK (Nb CAR-NK) cells using a synthetic nanobody identified from a phage display VHH library. The nanobody was selected after three rounds of biopanning and validated for high affinity and specificity using surface plasmon resonance and flow cytometry. The selected nanobody-based chimeric Ag receptor (Nb-CAR) construct was introduced into ex vivo expanded umbilical cord blood-derived NK cells via third-generation lentiviral transduction, resulting in stable expression and functional CAR-NK cells. The Nb CAR-NK cells exhibited potent cytotoxicity against MSLN-positive pancreatic cancer cells in vitro and significantly suppressed tumor growth in xenograft models. These findings support the clinical potential of Nb CAR-NK cells and highlight the value of Nb-CAR designs for targeting cell-surface Ags in solid tumors.

Schlagwörter

Stichwörter der Autor:innen

CAR-NKMesothelinNanobodyPancreatic cancer

Autor:innen und Institutionen

  • Department of Health Science, Graduate School of Dong-A University, Busan 49315, Korea.
  • Department of Medicinal Biotechnology, College of Health Science, Dong-A University, Busan 49315, Korea.
  • Bionanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea.
  • Osong Medical Innovation Foundation, Cheonju 28160, Korea.
  • Preclinical Research Center, Daegu-Gyeongbuk Medical Innovation Foundation (KMEDIHUB), Daegu 41061, Korea.
  • School of Pharmacy, Sungkyunkwan University, Suwon 16419, Korea.

ORCID-Profile: Dana Jung, Seokho Kim

Förderung

  • Korea Research Institute of Bioscience and Biotechnology
  • National Research Council of Science and Technology

Zitieren

APA

Jung, D., Choi, E., Jeoung, Y. H., Lee, J., Gong, E. Y., Jo, S. G., Noh, K., Ha, K., Wee, G., Kim, H., Jung, J., & Kim, S. (2025). Nanobody-Based CAR NK Cells for Possible Immunotherapy of Mesothelin + Tumors. Immune Network, 25(3). https://doi.org/10.4110/in.2025.25.e23

Vancouver

Jung D, Choi E, Jeoung YH, Lee J, Gong EY, Jo SG, et al. Nanobody-Based CAR NK Cells for Possible Immunotherapy of Mesothelin + Tumors. Immune Network. 2025;25(3). doi:10.4110/in.2025.25.e23

BibTeX
@article{Jung2025,
  author = {Jung, Dana and Choi, Eunjeong and Jeoung, Young-Hee and Lee, Juheon and Gong, Eun-Yeung and Jo, Seo-Gyeong and Noh, Kyunghee and Ha, Kyungsoo and Wee, Gabbine and Kim, Hyeran and Jung, Juyeon and Kim, Seokho},
  title = {Nanobody-Based CAR NK Cells for Possible Immunotherapy of Mesothelin + Tumors},
  journal = {Immune Network},
  year = {2025},
  volume = {25},
  number = {3},
  doi = {10.4110/in.2025.25.e23}
}
Kostenlos starten →